Medical Device | June 30, 2022
NADMED brings first CE-marked NAD+ analysis kit to the market
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.
First and only PARP inhibitor to improve invasive disease-free survival in patients
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
The three-year collaboration will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the next generation of molecular machine learning
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Tislelizumab is now approved in nine indications in China
Healthcare is timely and personal – and its delivery should be too
The £118 million Mazumdar-Shaw Advanced Research Centre (ARC) will be the creative and collaborative heart of cross-disciplinary research at the University of Glasgow.
Subscribe To Our Newsletter & Stay Updated
